Cardiff Oncology director buys stock and warrants
Cardiff Oncology, Inc. director Gary W. Pace reported open-market purchases dated 2026-07-14 of 687,285 shares of common stock at $1.455 per share and 687,285 common stock purchase warrants with an exercise price of $1.33 per share.
Rhea-AI Filing Summary
Cardiff Oncology, Inc. director Gary W. Pace reported open-market purchases dated 2026-07-14 of 687,285 shares of common stock at $1.455 per share and 687,285 common stock purchase warrants with an exercise price of $1.33 per share. Following these transactions he holds 2,043,661 common shares directly plus 687,285 warrants. The warrants become exercisable on the later of six months after issuance or the “Authorized Share Increase Date” and remain exercisable for five and one-half years after that Initial Exercise Date.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 1,374,570 shares
Net Buy
2 txns
Insider
PACE GARY W
Role
Director
Bought
1,374,570 shs ($1000K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock Purchase Warrant F1, F2 | 687,285 | $0.00 | $0.00 |
| Purchase | Common Stock | 687,285 | $1.455 | $1000K |
Holdings After Transaction:
Common Stock Purchase Warrant — 687,285 contracts (Direct);
Common Stock — 2,043,661 shares (Direct)
Footnotes (2)
- F1. Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders.
- F2. The term of exercise is equal to five and one-half years after the Initial Exercise Date.
Key Figures
Common stock purchased: 687,285 shares
Purchase price per share: $1.455
Common shares owned after purchase: 2,043,661 shares
+4 more
7 metrics
Common stock purchased
687,285 shares
Open-market purchase on 2026-07-14 by director Gary W. Pace
Purchase price per share
$1.455
Price paid for Cardiff Oncology common stock on 2026-07-14
Common shares owned after purchase
2,043,661 shares
Direct Cardiff Oncology common stock holdings of Gary W. Pace following the reported transactions
Warrants acquired
687,285 warrants
Common Stock Purchase Warrants acquired on 2026-07-14
Warrant exercise price
$1.33
Conversion or exercise price per share for the acquired warrants
Total shares bought (stock plus underlying)
1,374,570 shares
Total buy shares across common stock and underlying shares of purchased warrants
Warrant term
five and one-half years
Term of exercise after the Initial Exercise Date for the acquired warrants
Key Terms
Common Stock Purchase Warrant, Initial Exercise Date, Authorized Share Increase Date, certificate of incorporation
4 terms
Common Stock Purchase Warrant financial
"Security acquired was a Common Stock Purchase Warrant for 687,285 underlying shares."
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
Initial Exercise Date financial
"Exercisable beginning on the later of six months after issuance or the Authorized Share Increase Date (the Initial Exercise Date)."
certificate of incorporation regulatory
"An amendment to the issuer's certificate of incorporation must increase authorized shares for full warrant exercise."
A certificate of incorporation is an official government document that creates a corporation and records key facts such as its legal name, basic governance structure, and stock authorization—think of it as a company's birth certificate plus its basic rulebook. Investors care because it establishes the company’s legal existence, limits owners’ personal liability, and sets the framework for issuing shares and enforcing shareholder rights, which affects ownership, control and the company’s ability to raise capital.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cardiff Oncology (CRDF) disclose in this Form 4?
Cardiff Oncology (CRDF) reported that director Gary W. Pace purchased 687,285 common shares at $1.455 each and 687,285 common stock purchase warrants with a $1.33 exercise price, all in open-market transactions dated 2026-07-14.
What price did Gary W. Pace pay for CRDF common stock in this filing?
Gary W. Pace paid $1.455 per share for 687,285 shares of Cardiff Oncology common stock. These were reported as open-market purchases, indicating he bought the shares directly in the market rather than through option exercises or other derivative conversions.
What are the key terms of the Cardiff Oncology (CRDF) warrants Gary W. Pace acquired?
The acquired warrants cover 687,285 underlying shares at an exercise price of $1.33 per share. They become exercisable on the later of six months after issuance or the Authorized Share Increase Date and remain exercisable for five and one-half years after the Initial Exercise Date.
Does this Cardiff Oncology (CRDF) Form 4 show any insider sales?
No. The Form 4 shows only purchases by Gary W. Pace, with a total of 1,374,570 shares of exposure bought across common stock and underlying warrant shares, and reports 0 shares sold or disposed of in the period covered.
AI-generated analysis. How Rhea-AI works. Not financial advice.
